Ameet Mallik

Ameet Mallik

Chief Executive Officer at ADC THERAPEUTICS SA

Net worth: 3 M $ as of 31/10/2026

53 year
Health Technology
Commercial Services
Consumer Services

Profile

Ameet Mallik currently works at ADC Therapeutics SA, as President, Chief Executive Officer & Director from 2022.
Mr. Mallik also formerly worked at Cornerstone Pharmaceuticals, Inc., as Non-Executive Chairman, Rafael Holdings, Inc., as Director in 2022, Atara Biotherapeutics, Inc., as Independent Director from 2021 to 2025, Novartis Oncology, Inc., as Global Head-Marketing, Value & Access from 2015 to 2017, Novartis AG, as Executive Vice President & Head-US Oncology from 2017 to 2021, McKinsey & Co., Inc., as Associate Principal, and Sandoz International GmbH, as Head-Biopharmaceuticals & Oncology Injectables from 2009 to 2014.
Mr. Mallik received his undergraduate degree and graduate degree from Northwestern University and Masters Business Admin degree from The Wharton School of the University of Pennsylvania.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
30/06/2026 2,121,769 ( 1.66% ) 3 M $ 31/10/2026
10/06/2025 16,928 ( 0.17% ) 135 593 $ 31/10/2026

Ameet Mallik active positions

CompaniesPositionStart
ADC THERAPEUTICS SA Chief Executive Officer 09/05/2022

Former positions of Ameet Mallik

CompaniesPositionEnd
ATARA BIOTHERAPEUTICS, INC. Director/Board Member 03/09/2025
RAFAEL HOLDINGS, INC. Chief Executive Officer 01/02/2022
Corporate Officer/Principal 01/11/2015
Corporate Officer/Principal 01/04/2014
Corporate Officer/Principal -
See the detail of Ameet Mallik's experience

Education of Ameet Mallik

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

64

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10

Commercial Services

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Health Technology

Consumer Services

Health Technology

Finance